Assistance Fund: Porphyria

Funded
About
The Assistance Fund: Porphyria program offers vital support by providing financial assistance for those prescribed Panhematin, Givlaari, and Scenesse. Designed to aid U.S. citizens and permanent residents with a primary diagnosis of porphyria, the program ensures access to FDA-approved treatments by covering copays, coinsurance, deductibles, and other medical expenses. The Assistance Fund: Porphyria program highlights its commitment to patients' needs, including comprehensive income-based eligibility criteria and the flexibility to cover off-label drug use.
Insurance requirements: Commercially insured, Medicare / Medicaid
Enrollment Forms
Enrollment Form
Program Requirements
•Valid only for residents in the US and Puerto Rico
•Enrollment Required: Yes
•Coverage Required: No
•Needs Based: Yes
•Activation Required: No
Program Details
•Please note the following:
•1. Copay grant programs provide assistance for copays, coinsurance, and deductibles for FDAapproved treatment for the disease named in the disease program ONLY
•2. Financial assistance grant programs provide assistance for other eligible outofpocket costs, such as health insurance premiums and incidental medical expenses, in addition to copay, coinsurance, and deductible assistance on FDAapproved treatment for the disease named in the disease program
•3. This fund may cover offlabel drugs
•Copay and Financial assistance can be utilized by any innetwork pharmacy or site of care able to dispense the medication or provide treatment
•Program offers conditional approval of 30 days of immediate assistance for open programs where funding is available
•Patients will be asked to provide and verify demographic, insurance, and financial information (additional documentation may be requested)
•Approved patients will be granted assistance through the end of the calendar year unless otherwise specified for the applicable program